2-[1-甲基-5-(三氟甲基)吡唑-3-基]噻吩-5-甲醛 | 175202-93-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 噻吩类
• 中文名称: 2-[1-甲基-5-(三氟甲基)吡唑-3-基]噻吩-5-甲醛
• 中文别名: 2-[1-甲基-5-(三氟甲基)吡唑-3-基]-噻吩-5-羧醛
• 英文名称: 5-(1-methyl-5-trifluoromethyl-1H-pyrazol-3-yl)thiophene-2-carboxyaldehyde
• 英文别名: 5-(1-methyl-5-(trifluoromethyl)-1H-pyrazol-3-yl)thiophene-2-carbaldehyde；5-[1-methyl-5-(trifluoromethyl)-1H-pyrazol-3-yl]thiophene-2-carbaldehyde；2-((1-methyl-3-trifluoromethyl)pyrazol-5-yl)thiophene-5-carboxyaldehyde；5-(1-methyl-5-trifluoromethyl-1H-pyrazol-3-yl)-thiophene-2-carbaldehyde；5-[1-methyl-5-(trifluoromethyl)-1H-pyrazol-3-yl]-2-thiophenecarboxaldehyde；5-(1-methyl-5-trifluoromethyl-1 H-pyrazol-3-yl)-thiophene-2-carbaldehyde；5-[1-methyl-5-(trifluoromethyl)pyrazol-3-yl]thiophene-2-carbaldehyde
• CAS: 175202-93-4
• 化学式: C₁₀H₇F₃N₂OS
• 分子量: 260.24
• InChiKey: ITUYPRXQRPMRTL-UHFFFAOYSA-N

物化性质

• 熔点：
  76-78°C
• 沸点：
  366.3±42.0 °C(Predicted)
• 密度：
  1.46±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  17
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  63.1
• 氢给体数：
  0
• 氢受体数：
  6

安全信息

• 危险品标志：
  Xi
• 危险类别码：
  R20/21/22
• 海关编码：
  2934999090
• 安全说明：
  S26,S36/37/39

反应信息

• 作为反应物：
  描述：

  2-[1-甲基-5-(三氟甲基)吡唑-3-基]噻吩-5-甲醛 在 sodium hydroxide 、 silver nitrate 作用下， 以 乙醇 、 水 为溶剂， 反应 1.0h， 生成 5-(1-甲基-5-(三氟甲基)-1h-吡唑-3-在)噻吩-2-羧酸
  参考文献：
  名称：

  Pharmaceutical compound comprising a pyrazole derivative and methods of using the same for the treatment of calcium release-activated calcium channel associated diseases

  摘要：

  本发明涉及药物，特别是由以下一般式（I）表示的吡唑衍生物，其具有钙释放激活的钙通道抑制作用和药用组合物，特别是含有上述化合物作为活性成分的钙释放激活的钙通道抑制剂，其中每个取代基在规范中定义。本发明还涉及含有一定量的式（I）化合物和药效载体的药用组合物。本发明还涉及与钙释放激活的钙通道相关的疾病、与IL-2产生相关的疾病以及过敏、炎症或自身免疫疾病的治疗方法。

  公开号：

  US06348480B1

文献信息

• A phase-switch purification approach for the expedient removal of tagged reagents and scavengers following their application in organic synthesis
  作者：Jason Siu、Ian R. Baxendale、Russell A. Lewthwaite、Steven V. Ley

  DOI：10.1039/b503778f

  日期：——

  In this paper we wish to report on a variety of expedient chemical transformations and purifications achieved via a generic ‘catch and release’ methodology, based on a synthetically inert bipyridyl chelating tag that can be selectively captured with a resin-bound copper(II) species. Utilising this approach we are able to derive many of the same benefits associated with both solid phase synthesis and supported reagent methods.

  本文旨在报道通过一种基于合成不活跃的双吡啶螯合标签的通用“捕获与释放”方法，实现的一系列便捷的化学转化和纯化。该方法可以选择性地利用树脂结合的铜(II)物种来捕获双吡啶螯合标签。采用这种方法，我们能够获得与固相合成和支持试剂法相关的许多相同益处。
• MOF-derived cobalt nanoparticles catalyze a general synthesis of amines
  作者：Rajenahally V. Jagadeesh、Kathiravan Murugesan、Ahmad S. Alshammari、Helfried Neumann、Marga-Martina Pohl、Jörg Radnik、Matthias Beller

  DOI：10.1126/science.aan6245

  日期：2017.10.20

  preparation entailed template assembly of cobalt-diamine-dicarboxylic acid metal organic frameworks on carbon and subsequent pyrolysis under inert atmosphere. The resulting stable and reusable catalysts were active for synthesis of primary, secondary, tertiary, and N-methylamines (more than 140 examples). The reaction couples easily accessible carbonyl compounds (aldehydes and ketones) with ammonia, amines

  MOF 为制造胺奠定了基础 还原胺化是化学家用来制造碳氮键的常用方法。该反应通常需要贵金属催化剂，将氨或其他胺与羰基化合物偶联，然后与氢气偶联。贾加迪什等人。报告了一类非贵重的钴纳米粒子，可在非常广泛的底物上催化这种反应，包括具有药用价值的复杂分子（参见 Chen 和 Xu 的观点）。钴首先嵌入金属有机框架 (MOF) 中，加热后转变为石墨壳。催化剂可以方便地从产品中分离出来，最多可循环使用六次。科学，这个问题 p。326; 另见第。304 由金属-有机骨架前体制备的钴纳米颗粒可催化非常广泛的还原胺化反应。用于合成药物相关化合物的贱金属催化剂的开发仍然是化学研究的一个重要目标。在这里，我们报告说，由石墨壳包裹的钴纳米颗粒是广泛有效的还原胺化催化剂。它们方便实用的制备需要在碳上模板组装钴-二胺-二羧酸金属有机骨架，然后在惰性气氛下热解。所得稳定且可重复使用的催化剂对于合成伯胺、仲胺、叔胺和 N-甲胺（超过
• Development of fluorination methods using continuous-flow microreactors
  作者：Marcus Baumann、Ian R. Baxendale、Laetitia J. Martin、Steven V. Ley

  DOI：10.1016/j.tet.2009.05.083

  日期：2009.8

  The safe and reliable use of various fluorination methods including nucleophilic fluorination (DAST), trifluoromethylation (Ruppert's reagent) and electrophilic fluorination (Selectfluor®) in a continuous-flow microreactor is reported. Special attention was given to the use of in-line scavenging procedures in order to obtain clean products without the need for further purification.

  安全可靠的使用各种氟化方法，包括核氟化（DAST），三氟甲基化（鲁珀特试剂）和电氟化（的Selectfluor ®报道在连续流微反应器）。为了获得清洁的产品而无需进一步纯化，特别注意了使用在线清除程序。
• Heteroarylacrylamides and their use as pharmaceuticals for the stimulation of the expression of endothelial NO synthase
  申请人：sanofi-aventis

  公开号：EP1939180A1

  公开（公告）日：2008-07-02

  The present invention relates to heteroarylacrylamides of the formula I, in which Het, X, Ra, Rb, R1, R2 and R3 have the meanings indicated in the claims, which modulate the transcription of endothelial nitric oxide (NO) synthase and are valuable pharmacologically active compounds. Specifically, the compounds of the formula I upregulate the expression of the enzyme endothelial NO synthase and can be applied in conditions in which an increased expression of said enzyme or an increased NO level or the normalization of a decreased NO level is desired. The invention further relates to processes for the preparation of compounds of the formula I, to pharmaceutical compositions comprising them, and to the use of compounds of the formula I for the manufacture of a medicament for the stimulation of the expression of endothelial NO synthase or for the treatment of various diseases including cardiovascular disorders such as atherosclerosis, thrombosis, coronary artery disease, hypertension and cardiac insufficiency, for example.

  本发明涉及式I的杂环丙烯酰胺， 其中Het、X、Ra、Rb、R1、R2和R3具有权利要求中所示的含义，这些化合物调节内皮型一氧化氮（NO）合酶的转录，并且是有价值的药理活性化合物。具体地，式I的化合物上调内皮型一氧化氮合酶的表达，并可应用于需要增加该酶的表达或增加NO水平或恢复降低的NO水平的情况。本发明还涉及制备式I化合物的方法，包括它们的药物组合物，以及利用式I化合物制造用于刺激内皮型一氧化氮合酶表达或治疗各种疾病的药物，包括心血管疾病，如动脉粥样硬化、血栓形成、冠状动脉疾病、高血压和心脏功能不全等。
• Pharmaceutical compound comprising a pyrazole derivative and methods of using the same for the treatment of calcium release-activated calcium channel associated diseases
  申请人：Yamanouchi Pharmaceutical Co., Ltd.

  公开号：US06348480B1

  公开（公告）日：2002-02-19

  The present invention is directed to drugs, in particular, pyrazole derivatives represented by the following general formula (I) which have a calcium release-activated calcium channel inhibitory effect and medicinal compositions, in particular, calcium release-activated calcium channel inhibitors containing the above compounds as the active ingredient, wherein each substituent is defined in the specification. The present invention also relates to a pharmaceutical composition containiing an effective amount of the compound of formula (I) and a pharmaceutically effective carrier. The present invention further relates to methods of treatment of diseases associated with calcium release-activated calcium channels, diseases associated with IL-2 production, and methods of treatment of allergic, inflammatory or auto-immune diseases.

  本发明涉及药物，特别是由以下一般式（I）表示的吡唑衍生物，其具有钙释放激活的钙通道抑制作用和药用组合物，特别是含有上述化合物作为活性成分的钙释放激活的钙通道抑制剂，其中每个取代基在规范中定义。本发明还涉及含有一定量的式（I）化合物和药效载体的药用组合物。本发明还涉及与钙释放激活的钙通道相关的疾病、与IL-2产生相关的疾病以及过敏、炎症或自身免疫疾病的治疗方法。